WhatsApp
Call Us
K2m
ANGEL ONE
(₹20/Trade)
Open Account
MOTILAL OSWAL
Open Account
Stock Market Institue
Trial Class
Book Now


IPOs, NCDs, OFS, Rights Issues, Buyback and Stock Brokers

IPO Open

Thu, Jun 18, 2026

IPO Close

Mon, Jun 22, 2026

Price Band

₹196 to ₹208

Market Cap (Pre-IPO)

₹114.09 Cr

IPO Details

  • IPO Date
    18 to 22 Jun, 2026
  • Listing Date
    Thu, Jun 25, 2026T
  • Face Value
    ₹10 per share
  • Price Band
    ₹196 to ₹208
  • Lot Size
    600 Shares
  • Sale Type
    Fresh capital only
  • Issue Type
    Bookbuilding IPO
  • Listing At
    NSE SME
  • Total Issue Size
    14,53,800 shares (agg. up to ₹30 Cr)
  • Reserved for Market Maker
    82,200 shares (agg. up to ₹2 Cr) Asnani Stock Broker Pvt.Ltd.
  • Fresh Issue (Ex Market Maker)
    13,71,600 shares (agg. up to ₹29 Cr)
  • Net Offered to Public
    13,71,600 shares (agg. up to ₹29 Cr)
  • Share Holding Pre Issue
    40,31,256 shares
  • Share Holding Post Issue
    54,85,056 shares

IPO Timetable (Tentative)

  • IPO Open
    Thu, Jun 18, 2026
  • Allotment
    Tue, Jun 23, 2026
  • Credit of Shares
    Wed, Jun 24, 2026
  • IPO Close
    Mon, Jun 22, 2026
  • Refund
    Wed, Jun 24, 2026
  • Listing
    Thu, Jun 25, 2026

Issue Reservation

Avience Biomedicals IPO comprises a total issue size of 14,53,800 shares. The net offer to the public is 13,71,600 shares, after excluding 82,200 shares allotted on a firm basis. Of the Net offer 6,83,400 (49.83%) are allocated to QIB, 2,07,000 (15.09%) allocated to NII 4,81,200 (35.08%) allocated to RII.

Investor Category Shares Offered % of Net Issue % of Total Issue
QIB Shares Offered 6,83,400 49.83% 47.01%
  − Anchor Investor Shares Offered 4,09,800 28.19%
  − QIB (Ex. Anchor) Shares Offered 2,73,600 18.82%
NII (HNI) Shares Offered 2,07,000 15.09% 14.24%
  − bNII > ₹10L 1,38,000 9.49%
  − sNII < ₹10L 69,000 4.75%
Retail Shares Offered 4,81,200 35.08% 33.10%
Firm Reservations
Market Maker Shares Offered 82,200 5.65%
Total Shares Offered 14,53,800 100.00% 100.00%

IPO Lot Size

Investors can bid for a minimum of 1,200 shares and in multiples of 600 shares thereof.

Application Lots Shares Amount
Individual investors (IND) (Min) 2 1,200 ₹2,49,600
Individual investors (IND) (Max) 2 1,200 ₹2,49,600
S-HNI (Min) 3 1,800 ₹3,74,400
S-HNI (Max) 8 4,800 ₹9,98,400
B-HNI (Min) 9 5,400 ₹11,23,200

About Avience Biomedicals Ltd.

Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry.

Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusively on the B2B and B2G markets.

The company’s products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas.

In addition to manufacturing, the Company also act as distributors and traders of medical equipment.

The company’s manufacturing unit is situated in Noida, Uttar Pradesh.

The company offers a comprehensive range of diagnostic solutions, including:

  • Rapid Test Kits: Products like AVISURE Dengue Combo Test, Malaria Rapid Test (Pf/Pv), and AVISURE Syphilis Rapid Test.
  • Biochemistry Analyzers and Reagents: Devices like the BS-240 Fully Auto Analyzer and reagents like AVIENBIO Albumin Kit.
  • Molecular Diagnostics: COVID-19 detection kits, including the COVID-19 Hid RTqPCR ASSAY.
  • Hematology Analyzers: Models like the BC-20s 3-Part Hematology Analyzer.
  • Medical Devices: Oxygen concentrators (Oxy-5 and Oxy-10) and viral transport solutions (VTM).

As of January 31, 2026, the company had 75 permanent employees and 33 contractual employees

Competitive Strength

  • Strong Industry Experience and Expertise.
  • Avience provides various diagnostic products, including rapid test kits, analyzers, hematology devices, and molecular kits.
  • Strong distribution network across India and is growing its international footprint.
  • Cost-Effective and Affordable Solutions.
  • Stringent quality control processes and complies with ISO standards and regulatory approvals.

Company Financials (Restated Consolidated)

Period Ended 31 Jan 2026 31 Mar 2025 31 Mar 2024
Assets 66.07 56.52 34.65
Total Income 41.94 45.97 24.37
Profit After Tax 5.74 7.23 2.14
EBITDA 10.34 11.41 4.08
NET Worth 28.52 22.78 6.21
Reserves and Surplus 24.49 18.75 2.93
Total Borrowing 26.73 22.16 15.13
Amount in ₹ Crore

Recently Listed IPOs in Pharmaceuticals & Biotechnology

Company Issue Type Issue Size Issue Price Listing Day Close Listing Gain/Loss % LTP
Anthem Biosciences Ltd. Mainboard ₹3,395.00 Cr ₹570 ₹730.35 +28.13% ₹788.70 (+1.12%)

IPO Objects of the Issue

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:

  • # Issue Objects
    Est Amt (₹ Cr.)
  • 1 Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh
    15.96
  • 2 Funding the working capital requirements of the Company
    8.25
  • 3 General Corporate Purposes
  • Total
    24.21

Key Performance Indicator (KPI)

KPI Jan 31, 206 Mar 31, 2025
ROE 22.38% 50.14%
ROCE 16.99% 24.84%
Debt/Equity 0.94 0.97
RoNW 22.38% 49.89%
PAT Margin 15.86%
EBITDA Margin 24.70% 25.22%
Price to Book Value 2.94 3.68
Pre IPO Post IPO
EPS (₹) 17.94 12.56
P/E (x) 11.59 16.56
Promoter Holding 87.89% 64.59%
Market Cap ₹114.09 Cr.
Mr. Dharam Deo Choudhary, Mr. Ram Nagina Choudhary, Mr. Janardan Pal and Ms. Deepa Choudhary.
  • The value will be calculated using Equity Dilution = Share Holding Pre Issue – Share Holding Post Issue
  • The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2025 available in RHP.
  • The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of January 31, 2026 available in RHP.

IPO Stock Quote & Charts

Company Financials (Restated Standalone)

Period Ended Mar 31, 2024 Mar 31, 2025 Jan 31, 2026
Assets 25.63 43.60 51.96
Total Income 16.64 29.54 28.85
Profit After Tax 1.98 5.14 4.18
EBITDA 3.15 7.65 7.10
NET Worth 6.05 20.52 24.70
Reserves and Surplus 2.77 16.49 20.67
Total Borrowing 7.73 13.75 17.17

IPO Registrar

Skyline Financial Services Pvt.Ltd.

  • 02228511022
  • ipo@skylinerta.com
  • Visit Website

IPO Lead Manager(s)

  1. Fintellectual Corporate Advisors Pvt.Ltd.  (Past IPO Performance)

Lead Manager Reports

  • Lead Manager Performance Summary
  • Lead Manager Performance Tracker

Contact Details

Avience Biomedicals Ltd. Address
C-11, Block-C
Community Centre,
Janakpuri A-3,
Delhi, New Delhi, 110058

Stock Broker Reviews India

2.34/5
Angel One Limited

Delivery: Rs 20 per executed order Account Opening: Rs 0 (Free)

2.34/5
Angel One Limited

Delivery: Rs 20 per executed order Account Opening: Rs 0 (Free)

2.34/5
Angel One Limited

Delivery: Rs 20 per executed order Account Opening: Rs 0 (Free)

2.34/5
Angel One Limited 2

Delivery: Rs 20 per executed order Account Opening: Rs 0 (Free)

2.34/5
Angel One Limited

Delivery: Rs 20 per executed order Account Opening: Rs 0 (Free)

2.34/5
Angel One Limited

Delivery: Rs 20 per executed order Account Opening: Rs 0 (Free)

IPO FAQs

Avience Biomedicals IPO is a SME IPO of 14,53,800 equity shares of the face value of ₹10 aggregating up to ₹30 Crores. The issue is priced at ₹196 to ₹208. The minimum order quantity is 600.

The IPO opens on Thu, Jun 18, 2026, and closes on Mon, Jun 22, 2026.

Skyline Financial Services Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on NSE SME.

Angel One customers can apply online in Avience Biomedicals IPO using UPI as a payment gateway. Angel One customers can apply in Avience Biomedicals IPO by login into Angel One Console (back office) and submitting an IPO application form.

Steps to apply in Avience Biomedicals IPO through Angel One

Visit the Angel One website and login to Console.
Go to Portfolio and click the IPOs link.
Go to the ‘Avience Biomedicals IPO’ row and click the ‘Bid’ button.
Enter your UPI ID, Quantity, and Price.
Submit IPO application form.
Visit the UPI App (net banking or BHIM) to approve the mandate.
Visit Angel One IPO Application Process Review for more detail.

The Avience Biomedicals IPO opens on Thu, Jun 18, 2026 and closes on Mon, Jun 22, 2026.

Avience Biomedicals IPO lot size is 600, and the minimum amount required for application is ₹2,49,600, with 2 lots being the minimum application size.

You can apply in Avience Biomedicals IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don’t offer banking services. Read more detail about applying IPO online through Angel One, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.

The finalization of Basis of Allotment for Avience Biomedicals IPO will be done on Tuesday, June 23, 2026, and the allotted shares will be credited to your demat account by Wed, Jun 24, 2026. Check the Avience Biomedicals IPO allotment status.

The Avience Biomedicals IPO listing date is not yet announced. The tentative date of listing is Thu, Jun 25, 2026.

Advertisments

Compare India's most trusted brokers side-by-side to find your perfect match.